ArticleAnnals of clinical and translational neurology2021
Disease progression in Parkinson's disease patients with subjective cognitive complaint.
Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Subjective cognitive complaints in cognitively unimpaired Parkinson's disease: Associations with affective burden, motor severity, and awareness-related processes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Gait Analysis for Identifying Normal Cognition, Subjective Cognitive Decline, and Mild Cognitive Impairment in Parkinson Disease: Diagnostic Study.JMIR mHealth and uHealth · 2026Article
- CSF Biomarker-Based Cognitive Trajectories in Parkinson's Disease-Subjective Cognitive Decline.Annals of clinical and translational neurology · 2025Article
- The Role of Cognitive Reserve in Coping with Subjective Cognitive Complaints: An Exploratory Study of People with Parkinson's Disease (PwPD).Brain sciences · 2025Article
- Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline.Journal of neurology · 2025Article
- Article
- Neurocognitive Impairment and Social Cognition in Parkinson's Disease Patients.Neurology international · 2024Review
- Effects of Rehabilitation Training on Cognitive Function in Parkinson's Disease with Subjective Cognitive Decline.Neuropsychiatric disease and treatment · 2024Article
- Capturing subjective cognitive decline with a new combined index in low education patients with Parkinson's disease.Frontiers in neurology · 2024Article
- Subjective Cognitive Complaints in Cognitively Normal Patients With Parkinson's Disease: A Systematic Review.Journal of movement disorders · 2023Article
- Subjective cognitive decline in patients with Parkinson's disease: an updated review.Frontiers in aging neuroscience · 2023Review
- Different associated factors of subjective cognitive complaints in patients with early and advanced Parkinson's disease.Frontiers in aging neuroscience · 2023Article
- Subjective cognitive complaints in patients with progressive supranuclear palsy.Frontiers in neurology · 2023Article
- The pathobiological basis of depression in Parkinson disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Prevalence and affective correlates of subjective cognitive decline in patients with de novo Parkinson's disease.Acta neurologica Scandinavica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLittle is known about the disease progression of Parkinson's disease patients with subjective cognitive complaint (PD-SCC). This longitudinal cohort study aims to compare the progression of clinical features and quality of life (QoL) in PD patients with normal cognition (NC), SCC, and mild cognitive impairment (MCI).
methodsA total of 383 PD patients were enrolled, including 189 PD-NC patients, 59 PD-SCC patients, and 135 PD-MCI patients, with 1-7 years of follow-up. Linear mixed models were applied to evaluate longitudinal changes in motor symptoms, nonmotor features (cognitive impairment, depression, and excessive daytime sleepiness), and QoL in PD.
resultsAt baseline, PD-SCC patients had lower Beck Depression Inventory (BDI) scores and Parkinson's Disease Questionnaire-39 (PDQ-39) scores than PD-NC patients (all p < 0.05). Longitudinal analyses revealed that the PD-SCC group exhibited faster progression in terms of BDI scores (p = 0.042) and PDQ-39 scores (p = 0.035) than the PD-NC group. The PD-MCI group exhibited faster progression rates in the Epworth Sleepiness Scale scores (p = 0.001) and PDQ-39 scores (p = 0.005) than the PD-NC group. In addition, the PD-SCC group exhibited a greater reduction in attention (Trail Making Test Part A, p = 0.047) and executive function (Stroop Color-Word Test, p = 0.037) than the PD-NC group.
interpretationPD-SCC patients exhibited faster deterioration of depression and QoL than PD-NC patients, and SCC may be an indicator of initial attention and executive function decline in PD. Our findings provided a more accurate prognosis in PD-SCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.